Algorae Pharmaceuticals Limited (1AI)

Overview

Algorae Pharmaceuticals Limited is an innovative biotechnology entity based in Melbourne, Australia, with a focused mission on tackling debilitating neurological disorders. Originally established in 1987 as Living Cell Technologies Limited, the company underwent a rebranding to Algorae Pharmaceuticals Limited in September 2023. This transition reflects its evolving strategy and expanded commitment towards developing advanced therapeutic solutions. At its core, Algorae Pharmaceuticals is dedicated to confronting Parkinson's disease, a complex neurodegenerative disorder, by leveraging cutting-edge biotechnological approaches. Additionally, the company is exploring treatment avenues for dementia, including Alzheimer's disease, thereby broadening its impact on neurodegenerative disease management.

Products and Services

NTCELL for Parkinson's Disease

Algorae Pharmaceuticals is at the forefront of biotechnological innovation with its development of NTCELL, an alginate-coated capsule designed as a targeted treatment for Parkinson's disease. This inventive product represents a significant leap in Parkinson's disease therapy, focusing on bioengineered cell encapsulation technology to potentially halt or reverse the progression of this debilitating condition.

AI-116 for Dementia and Alzheimer's Disease

In addition to NTCELL, Algorae Pharmaceuticals is pioneering AI-116, a novel combination drug candidate. AI-116 ingeniously integrates cannabidiol with an off-patent pharmaceutical ingredient to formulate a promising therapeutic option for treating dementia, including Alzheimer's disease. This approach signifies Algorae Pharmaceuticals' dedication to expanding its therapeutic portfolio to address a broader spectrum of neurodegenerative diseases with innovative solutions.